• No products in the cart.


Multidisciplinary management, standards of care, optimal diagnostics, therapies and future perspectives in the care of Sickle Cell patients in sub-Saharan Africa.

Lead Faculty: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist

Executive Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com

Website: www.intercancer.com

This activity is supported by an educational grant from BMSF.


  1. Prof. Anne Greist– Hematologist and Medical Oncologist
  2. Prof. Riyat Malkit-Consultant Hematologist
  3. Dr. Zipporah Ali- Palliative Care Specialist
  4. Dr. Festus Njuguna– Pediatrician (Hematology/ Oncology)
  5. Dr. Gilbert Olbara-Pediatrician & Heme/Onc (Fellow)
  6. Dr. Hussein Elias- Palliative Care Specialist/Family Medicine

This course is accredited by:

Accredited by KMPDB
Accredited by KMPDB


Accredited by KPPB
Accredited by KPPB
Accredited by COC
Accredited by COC






Target Audience

The primary target audience for this course comprises the multidisciplinary clinical Sickle Cell care team members including, but not limited to physicians; fellows; residents; researchers; SCD nurse practitioners and SCD nurses; SCD pharmacists; SCD PharmTechs; SCD clinical officers; physician assistants; Laboratory scientists and technicians and other allied health care professionals.


At the end of this educational activity, participants should be able to:

  1. Describe the epidemiology, molecular basis, presentation and natural history of SCD and the variant sickle cell syndromes
  2. Describe the techniques for Screening and the diagnosis of SCD; Correctly interpret electrophoresis and HPLC traces
  3. Understand the pathophysiology and clinical manifestations of sickle cell disease: acute pain crises and progressive organ damage.
  4. Describe the management of specific major acute complications, including the acute chest syndrome, painful crisis, stroke etc
  5. Describe the long-term complications of SCD (including orthopaedic, ophthalmic, renal, pulmonary, endocrine and fertility issues) and their management, in particular, the need for comprehensive multidisciplinary care
  6. Understand the use of disease-modifying agents in the management of SCD
  7. Understand gene therapy, stem cell transplant and novel therapies in SCD treatment
  8. Explain appropriate use of transfusion in SCD
  9. Describe the complications, assessment and treatment of transfusional iron overload
  10. Demonstrate a working knowledge and practical competency for acute and chronic pain management in patients with sickle cell disease.
  11. Design a Health maintenance program for Pediatrics, Adolescents and Young Adults with SCD

Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labelled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit.

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

The Program


  1. Orientation to the course (Chite) Tuesday 12th May 2020 4:00-4:30 PM EAT
  2. Epidemiology, Molecular basis, Presentation and natural history of SCD (Festus) Thursday, 14th May 2020 4:00-5:30 PM EAT
  3. Screening and the diagnosis of SCD (Anne) Tuesday, 19th May 2020 4:00-5:30 PM EAT
  4. Pathophysiology and Clinical Manifestations of SCD (Anne) Thursday, 21st May 2020 4:00-5:30 PM EAT
  5. Management of acute complications of SCD (Riyat) Tuesday, 26th May 2020 4:00-5:30 PM EAT
  6. Long-term complications of SCD and Management I (Anne) Thursday, 28th May 2020 4:00-5:30 PM EAT.
  7. Long-term complications of SCD and Management II (Anne) Tuesday, 2nd June 2020 4:00-5:30 PM EAT
  8. Disease-modifying agents in the management of SCD (Gilbert) Thursday, 4th June 2020 4:00-5:30 PM EAT
  9. Gene therapy, stem cell transplant and novel therapies in SCD treatment (Anne) Tuesday, 9th June 2020 4:00-5:30 PM EAT
  10. Transfusion in SCD (Riyat) Thursday, 11th June 2020 4:00-5:30 PM EAT
  11. Iron overload management in SCD (Chite)Tuesday, 16th June 2020 4:00-5:30 PM EAT
  12. Acute and Chronic pain management in patients with sickle cell disease. (Zippy/Hussein) Thursday, 18th June 2020 4:00-5:30 PM EAT
  13. Health maintenance in SCD (Gilbert) Tuesday 23rd June 2020 4:00-5:30 PM EAT
  14. Psychosocial Issues in SCD Management (TBD/Chite) Thursday, 25th June 2020 4:00-5:30 PM EAT
  15. Case discussions in SCD management (Anne/Chite) Tuesday, 30th June 2020 4:00-5:30 PM EAT
  16. Improving SCD transitions of Care: From Pediatrics to Young Adult (Riyat) Thursday, 2nd July 2020 4:00- 5:30 PM EAT

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours)

All those interested in registration to this course, please send your application  information to info@intercancer.com


ICI Acknowledges that the funding for this preceptorship training has been proudly supported by the Bristol-Myers Squibb Foundation (BMSF) Secure the Future Programme.

Course Reviews


3 ratings
  • 5 stars1
  • 4 stars2
  • 3 stars0
  • 2 stars0
  • 1 stars0
  1. 5

    Very informative. Thank you.

  2. was a good learning platform despite the network issues and busy schedule



  3. 4

    Very informative with crucial and timely updates

© 2022 International Cancer Institute. All Rights Reserved